Loading…
Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma
Inhibitors of the mitogen-activated protein kinases (MAPK), BRAF, and MAP-ERK kinase (MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic melanoma. The clinical benefit of MAPK inhibitors is restricted by the development of acquired resistance with half of those who...
Saved in:
| Published in: | Molecular cancer therapeutics 2013-07, Vol.12 (7), p.1332-1342 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c356t-8e8017a2b05be4345e3212d722a14fd449ebe96960c6b8658377ac1c65642bd83 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c356t-8e8017a2b05be4345e3212d722a14fd449ebe96960c6b8658377ac1c65642bd83 |
| container_end_page | 1342 |
| container_issue | 7 |
| container_start_page | 1332 |
| container_title | Molecular cancer therapeutics |
| container_volume | 12 |
| creator | Carlino, Matteo S Gowrishankar, Kavitha Saunders, Catherine A B Pupo, Gulietta M Snoyman, Stephanie Zhang, Xu Dong Saw, Robyn Becker, Therese M Kefford, Richard F Long, Georgina V Rizos, Helen |
| description | Inhibitors of the mitogen-activated protein kinases (MAPK), BRAF, and MAP-ERK kinase (MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic melanoma. The clinical benefit of MAPK inhibitors is restricted by the development of acquired resistance with half of those who benefit having progressed by 6 to 7 months and long-term responders uncommon. There remains no agreed treatment strategy on disease progression in these patients. Without published evidence, fears of accelerated disease progression on inhibitor withdrawal have led to the continuation of drugs beyond formal disease progression. We now show that treatment with MAPK inhibitors beyond disease progression can provide significant clinical benefit, and the withdrawal of these inhibitors led to a marked increase in the rate of disease progression in two patients. We also show that MAPK inhibitors retain partial activity in acquired resistant melanoma by examining drug-resistant clones generated to dabrafenib, trametinib, or the combination of these drugs. All resistant sublines displayed a markedly slower rate of proliferation when exposed to MAPK inhibitors, and this coincided with a reduction in MAPK signaling, decrease in bromodeoxyuridine incorporation, and S-phase inhibition. This cytostatic effect was also associated with diminished levels of cyclin D1 and p-pRb. Two short-term melanoma cultures generated from resistant tumor biopsies also responded to MAPK inhibition, with comparable inhibitory changes in proliferation and MAPK signaling. These data provide a rationale for the continuation of BRAF and MEK inhibitors after disease progression and support the development of clinical trials to examine this strategy. |
| doi_str_mv | 10.1158/1535-7163.MCT-13-0011 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1399265568</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1399265568</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-8e8017a2b05be4345e3212d722a14fd449ebe96960c6b8658377ac1c65642bd83</originalsourceid><addsrcrecordid>eNpNkVFv1SAUx4nRuDn9CBoefenWA4XSx-vNpsYtJsv2TCg93dAW7oBu2dfxk0q9c9kT5PD7HeD8CfkI9TGAUCcguKhakPz4YntVAa_qGuAVOSx1VSkBzet_-z1zQN6l9KsQqmPwlhwwLhshOjgkfzY-u10MkxsxmuzukeI4os2JhpHaUE79ggOdXQ436CtjC2NyqRQpo_P0t_MmId2ZfPtgHqnzt6532QVPxzBN4cH5G2rs3eJikSIml7LxFmkO9Mvl5owaP5yESC9Of7x0S-MZJ-PDbN6TN6OZEn54Wo_I9dnp1fZbdf7z6_ft5ryyXMhcKVQ1tIb1teix4Y1AzoANLWMGmnFomg577GQnayt7JYXibWssWClkw_pB8SPyed-3_OxuwZT17JLFqbwCw5I08K5jUgi5omKP2hhSijjqXXSziY8aar3Go9fR63X0usRTVL3GU7xPT1cs_YzDs_U_D_4XkjmOuA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1399265568</pqid></control><display><type>article</type><title>Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma</title><source>EZB Electronic Journals Library</source><creator>Carlino, Matteo S ; Gowrishankar, Kavitha ; Saunders, Catherine A B ; Pupo, Gulietta M ; Snoyman, Stephanie ; Zhang, Xu Dong ; Saw, Robyn ; Becker, Therese M ; Kefford, Richard F ; Long, Georgina V ; Rizos, Helen</creator><creatorcontrib>Carlino, Matteo S ; Gowrishankar, Kavitha ; Saunders, Catherine A B ; Pupo, Gulietta M ; Snoyman, Stephanie ; Zhang, Xu Dong ; Saw, Robyn ; Becker, Therese M ; Kefford, Richard F ; Long, Georgina V ; Rizos, Helen</creatorcontrib><description>Inhibitors of the mitogen-activated protein kinases (MAPK), BRAF, and MAP-ERK kinase (MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic melanoma. The clinical benefit of MAPK inhibitors is restricted by the development of acquired resistance with half of those who benefit having progressed by 6 to 7 months and long-term responders uncommon. There remains no agreed treatment strategy on disease progression in these patients. Without published evidence, fears of accelerated disease progression on inhibitor withdrawal have led to the continuation of drugs beyond formal disease progression. We now show that treatment with MAPK inhibitors beyond disease progression can provide significant clinical benefit, and the withdrawal of these inhibitors led to a marked increase in the rate of disease progression in two patients. We also show that MAPK inhibitors retain partial activity in acquired resistant melanoma by examining drug-resistant clones generated to dabrafenib, trametinib, or the combination of these drugs. All resistant sublines displayed a markedly slower rate of proliferation when exposed to MAPK inhibitors, and this coincided with a reduction in MAPK signaling, decrease in bromodeoxyuridine incorporation, and S-phase inhibition. This cytostatic effect was also associated with diminished levels of cyclin D1 and p-pRb. Two short-term melanoma cultures generated from resistant tumor biopsies also responded to MAPK inhibition, with comparable inhibitory changes in proliferation and MAPK signaling. These data provide a rationale for the continuation of BRAF and MEK inhibitors after disease progression and support the development of clinical trials to examine this strategy.</description><identifier>ISSN: 1535-7163</identifier><identifier>EISSN: 1538-8514</identifier><identifier>DOI: 10.1158/1535-7163.MCT-13-0011</identifier><identifier>PMID: 23645591</identifier><language>eng</language><publisher>United States</publisher><subject>Apoptosis - drug effects ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; Gene Expression ; Humans ; Imidazoles - adverse effects ; Imidazoles - therapeutic use ; Male ; Melanoma - drug therapy ; Melanoma - pathology ; Middle Aged ; Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors ; Mitogen-Activated Protein Kinase Kinases - metabolism ; Oximes - adverse effects ; Oximes - therapeutic use ; Proto-Oncogene Proteins B-raf - antagonists & inhibitors ; Proto-Oncogene Proteins B-raf - metabolism ; Pyridones - adverse effects ; Pyridones - therapeutic use ; Pyrimidinones - adverse effects ; Pyrimidinones - therapeutic use</subject><ispartof>Molecular cancer therapeutics, 2013-07, Vol.12 (7), p.1332-1342</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-8e8017a2b05be4345e3212d722a14fd449ebe96960c6b8658377ac1c65642bd83</citedby><cites>FETCH-LOGICAL-c356t-8e8017a2b05be4345e3212d722a14fd449ebe96960c6b8658377ac1c65642bd83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23645591$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carlino, Matteo S</creatorcontrib><creatorcontrib>Gowrishankar, Kavitha</creatorcontrib><creatorcontrib>Saunders, Catherine A B</creatorcontrib><creatorcontrib>Pupo, Gulietta M</creatorcontrib><creatorcontrib>Snoyman, Stephanie</creatorcontrib><creatorcontrib>Zhang, Xu Dong</creatorcontrib><creatorcontrib>Saw, Robyn</creatorcontrib><creatorcontrib>Becker, Therese M</creatorcontrib><creatorcontrib>Kefford, Richard F</creatorcontrib><creatorcontrib>Long, Georgina V</creatorcontrib><creatorcontrib>Rizos, Helen</creatorcontrib><title>Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma</title><title>Molecular cancer therapeutics</title><addtitle>Mol Cancer Ther</addtitle><description>Inhibitors of the mitogen-activated protein kinases (MAPK), BRAF, and MAP-ERK kinase (MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic melanoma. The clinical benefit of MAPK inhibitors is restricted by the development of acquired resistance with half of those who benefit having progressed by 6 to 7 months and long-term responders uncommon. There remains no agreed treatment strategy on disease progression in these patients. Without published evidence, fears of accelerated disease progression on inhibitor withdrawal have led to the continuation of drugs beyond formal disease progression. We now show that treatment with MAPK inhibitors beyond disease progression can provide significant clinical benefit, and the withdrawal of these inhibitors led to a marked increase in the rate of disease progression in two patients. We also show that MAPK inhibitors retain partial activity in acquired resistant melanoma by examining drug-resistant clones generated to dabrafenib, trametinib, or the combination of these drugs. All resistant sublines displayed a markedly slower rate of proliferation when exposed to MAPK inhibitors, and this coincided with a reduction in MAPK signaling, decrease in bromodeoxyuridine incorporation, and S-phase inhibition. This cytostatic effect was also associated with diminished levels of cyclin D1 and p-pRb. Two short-term melanoma cultures generated from resistant tumor biopsies also responded to MAPK inhibition, with comparable inhibitory changes in proliferation and MAPK signaling. These data provide a rationale for the continuation of BRAF and MEK inhibitors after disease progression and support the development of clinical trials to examine this strategy.</description><subject>Apoptosis - drug effects</subject><subject>Cell Line, Tumor</subject><subject>Drug Resistance, Neoplasm</subject><subject>Gene Expression</subject><subject>Humans</subject><subject>Imidazoles - adverse effects</subject><subject>Imidazoles - therapeutic use</subject><subject>Male</subject><subject>Melanoma - drug therapy</subject><subject>Melanoma - pathology</subject><subject>Middle Aged</subject><subject>Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors</subject><subject>Mitogen-Activated Protein Kinase Kinases - metabolism</subject><subject>Oximes - adverse effects</subject><subject>Oximes - therapeutic use</subject><subject>Proto-Oncogene Proteins B-raf - antagonists & inhibitors</subject><subject>Proto-Oncogene Proteins B-raf - metabolism</subject><subject>Pyridones - adverse effects</subject><subject>Pyridones - therapeutic use</subject><subject>Pyrimidinones - adverse effects</subject><subject>Pyrimidinones - therapeutic use</subject><issn>1535-7163</issn><issn>1538-8514</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNpNkVFv1SAUx4nRuDn9CBoefenWA4XSx-vNpsYtJsv2TCg93dAW7oBu2dfxk0q9c9kT5PD7HeD8CfkI9TGAUCcguKhakPz4YntVAa_qGuAVOSx1VSkBzet_-z1zQN6l9KsQqmPwlhwwLhshOjgkfzY-u10MkxsxmuzukeI4os2JhpHaUE79ggOdXQ436CtjC2NyqRQpo_P0t_MmId2ZfPtgHqnzt6532QVPxzBN4cH5G2rs3eJikSIml7LxFmkO9Mvl5owaP5yESC9Of7x0S-MZJ-PDbN6TN6OZEn54Wo_I9dnp1fZbdf7z6_ft5ryyXMhcKVQ1tIb1teix4Y1AzoANLWMGmnFomg577GQnayt7JYXibWssWClkw_pB8SPyed-3_OxuwZT17JLFqbwCw5I08K5jUgi5omKP2hhSijjqXXSziY8aar3Go9fR63X0usRTVL3GU7xPT1cs_YzDs_U_D_4XkjmOuA</recordid><startdate>201307</startdate><enddate>201307</enddate><creator>Carlino, Matteo S</creator><creator>Gowrishankar, Kavitha</creator><creator>Saunders, Catherine A B</creator><creator>Pupo, Gulietta M</creator><creator>Snoyman, Stephanie</creator><creator>Zhang, Xu Dong</creator><creator>Saw, Robyn</creator><creator>Becker, Therese M</creator><creator>Kefford, Richard F</creator><creator>Long, Georgina V</creator><creator>Rizos, Helen</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201307</creationdate><title>Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma</title><author>Carlino, Matteo S ; Gowrishankar, Kavitha ; Saunders, Catherine A B ; Pupo, Gulietta M ; Snoyman, Stephanie ; Zhang, Xu Dong ; Saw, Robyn ; Becker, Therese M ; Kefford, Richard F ; Long, Georgina V ; Rizos, Helen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-8e8017a2b05be4345e3212d722a14fd449ebe96960c6b8658377ac1c65642bd83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Apoptosis - drug effects</topic><topic>Cell Line, Tumor</topic><topic>Drug Resistance, Neoplasm</topic><topic>Gene Expression</topic><topic>Humans</topic><topic>Imidazoles - adverse effects</topic><topic>Imidazoles - therapeutic use</topic><topic>Male</topic><topic>Melanoma - drug therapy</topic><topic>Melanoma - pathology</topic><topic>Middle Aged</topic><topic>Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors</topic><topic>Mitogen-Activated Protein Kinase Kinases - metabolism</topic><topic>Oximes - adverse effects</topic><topic>Oximes - therapeutic use</topic><topic>Proto-Oncogene Proteins B-raf - antagonists & inhibitors</topic><topic>Proto-Oncogene Proteins B-raf - metabolism</topic><topic>Pyridones - adverse effects</topic><topic>Pyridones - therapeutic use</topic><topic>Pyrimidinones - adverse effects</topic><topic>Pyrimidinones - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carlino, Matteo S</creatorcontrib><creatorcontrib>Gowrishankar, Kavitha</creatorcontrib><creatorcontrib>Saunders, Catherine A B</creatorcontrib><creatorcontrib>Pupo, Gulietta M</creatorcontrib><creatorcontrib>Snoyman, Stephanie</creatorcontrib><creatorcontrib>Zhang, Xu Dong</creatorcontrib><creatorcontrib>Saw, Robyn</creatorcontrib><creatorcontrib>Becker, Therese M</creatorcontrib><creatorcontrib>Kefford, Richard F</creatorcontrib><creatorcontrib>Long, Georgina V</creatorcontrib><creatorcontrib>Rizos, Helen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular cancer therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carlino, Matteo S</au><au>Gowrishankar, Kavitha</au><au>Saunders, Catherine A B</au><au>Pupo, Gulietta M</au><au>Snoyman, Stephanie</au><au>Zhang, Xu Dong</au><au>Saw, Robyn</au><au>Becker, Therese M</au><au>Kefford, Richard F</au><au>Long, Georgina V</au><au>Rizos, Helen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma</atitle><jtitle>Molecular cancer therapeutics</jtitle><addtitle>Mol Cancer Ther</addtitle><date>2013-07</date><risdate>2013</risdate><volume>12</volume><issue>7</issue><spage>1332</spage><epage>1342</epage><pages>1332-1342</pages><issn>1535-7163</issn><eissn>1538-8514</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><notes>ObjectType-Report-3</notes><notes>ObjectType-Case Study-4</notes><abstract>Inhibitors of the mitogen-activated protein kinases (MAPK), BRAF, and MAP-ERK kinase (MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic melanoma. The clinical benefit of MAPK inhibitors is restricted by the development of acquired resistance with half of those who benefit having progressed by 6 to 7 months and long-term responders uncommon. There remains no agreed treatment strategy on disease progression in these patients. Without published evidence, fears of accelerated disease progression on inhibitor withdrawal have led to the continuation of drugs beyond formal disease progression. We now show that treatment with MAPK inhibitors beyond disease progression can provide significant clinical benefit, and the withdrawal of these inhibitors led to a marked increase in the rate of disease progression in two patients. We also show that MAPK inhibitors retain partial activity in acquired resistant melanoma by examining drug-resistant clones generated to dabrafenib, trametinib, or the combination of these drugs. All resistant sublines displayed a markedly slower rate of proliferation when exposed to MAPK inhibitors, and this coincided with a reduction in MAPK signaling, decrease in bromodeoxyuridine incorporation, and S-phase inhibition. This cytostatic effect was also associated with diminished levels of cyclin D1 and p-pRb. Two short-term melanoma cultures generated from resistant tumor biopsies also responded to MAPK inhibition, with comparable inhibitory changes in proliferation and MAPK signaling. These data provide a rationale for the continuation of BRAF and MEK inhibitors after disease progression and support the development of clinical trials to examine this strategy.</abstract><cop>United States</cop><pmid>23645591</pmid><doi>10.1158/1535-7163.MCT-13-0011</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1535-7163 |
| ispartof | Molecular cancer therapeutics, 2013-07, Vol.12 (7), p.1332-1342 |
| issn | 1535-7163 1538-8514 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1399265568 |
| source | EZB Electronic Journals Library |
| subjects | Apoptosis - drug effects Cell Line, Tumor Drug Resistance, Neoplasm Gene Expression Humans Imidazoles - adverse effects Imidazoles - therapeutic use Male Melanoma - drug therapy Melanoma - pathology Middle Aged Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors Mitogen-Activated Protein Kinase Kinases - metabolism Oximes - adverse effects Oximes - therapeutic use Proto-Oncogene Proteins B-raf - antagonists & inhibitors Proto-Oncogene Proteins B-raf - metabolism Pyridones - adverse effects Pyridones - therapeutic use Pyrimidinones - adverse effects Pyrimidinones - therapeutic use |
| title | Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T15%3A15%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiproliferative%20effects%20of%20continued%20mitogen-activated%20protein%20kinase%20pathway%20inhibition%20following%20acquired%20resistance%20to%20BRAF%20and/or%20MEK%20inhibition%20in%20melanoma&rft.jtitle=Molecular%20cancer%20therapeutics&rft.au=Carlino,%20Matteo%20S&rft.date=2013-07&rft.volume=12&rft.issue=7&rft.spage=1332&rft.epage=1342&rft.pages=1332-1342&rft.issn=1535-7163&rft.eissn=1538-8514&rft_id=info:doi/10.1158/1535-7163.MCT-13-0011&rft_dat=%3Cproquest_cross%3E1399265568%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c356t-8e8017a2b05be4345e3212d722a14fd449ebe96960c6b8658377ac1c65642bd83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1399265568&rft_id=info:pmid/23645591&rfr_iscdi=true |